Alnylam's Revenue Surges, Nucresiran Trial Expansion Signals Accelerated Growth
Event summary
- Alnylam reported $1.17 billion in total revenue for Q1 2026, a 96% increase year-over-year.
- AMVUTTRA and ONPATTRO generated $910 million and $20 million in net product revenues, respectively, representing 153% total TTR growth.
- The Phase 3 TRITON-CM trial for nucresiran is expanding enrollment from 1,250 to 1,750 patients due to faster-than-anticipated recruitment.
- Alnylam initiated a Phase 1 trial for ALN-2232, an adipose-targeted RNAi therapeutic for obesity and weight management.
The big picture
Alnylam's strong Q1 2026 results underscore the growing demand for RNAi therapeutics, particularly in rare diseases like ATTR amyloidosis. The expansion of the nucresiran trial and entry into the obesity market signal an aggressive growth strategy, but also introduce new execution risks. The company's ability to maintain its leadership position will depend on successfully navigating regulatory hurdles, managing competition, and demonstrating the long-term value of its pipeline.
What we're watching
- Enrollment Pace
- The accelerated enrollment in the TRITON-CM trial suggests a higher-than-expected demand for ATTR-CM therapies, potentially impacting nucresiran's launch timeline and competitive landscape.
- Adipose Targeting
- The initiation of the ALN-2232 Phase 1 trial marks Alnylam's foray into the obesity market, a space attracting significant investment and scrutiny, and its success will hinge on demonstrating efficacy and safety in a complex biological environment.
- Commercial Dynamics
- The continued growth of AMVUTTRA, despite ONPATTRO's decline, will be critical to sustaining Alnylam's overall revenue trajectory and will require ongoing market differentiation and patient access strategies.
Related topics